首页> 外国专利> THERAPY AND METHODS OF INTRODUCING IMMATURE DENDRITIC CELLS AND/OR CYTOXIC T LYMPHOCYTE AND ANTI PD-1 / PD-L1 ANTIBODY FOR TREATMENT OF TUMORS

THERAPY AND METHODS OF INTRODUCING IMMATURE DENDRITIC CELLS AND/OR CYTOXIC T LYMPHOCYTE AND ANTI PD-1 / PD-L1 ANTIBODY FOR TREATMENT OF TUMORS

机译:引入未成熟树突状细胞和/或细胞毒性T淋巴细胞和抗PD-1 / PD-L1抗体治疗肿瘤的方法和方法

摘要

The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of PD-1 and/or PD-L1 inhibitor into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the PD-1 and/or PD-L1 inhibitor is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.
机译:本发明涉及疗法和将疗法应用于患者的方法。本发明包括将未成熟树突细胞引入患者体内以及将PD-1和/或PD-L1抑制剂引入患者体内。未成熟的树突状细胞是通过肿瘤内和/或通过血管引入的,而PD-1和/或PD-L1抑制剂是通过肿瘤内和/或通过血管和/或皮下引入的。未成熟的树突状细胞可以通过收集来自患者的单核细胞并在培养基中培养而形成。本发明可以有效地消退,减少或消除患者肿瘤组织中包括转移肿瘤的肿瘤细胞。此外,本发明的治疗在不存在常规疗法如放射疗法和化学疗法的情况下是有效的。

著录项

  • 公开/公告号US2020030375A1

    专利类型

  • 公开/公告日2020-01-30

    原文格式PDF

  • 申请/专利权人 KENICHIRO HASUMI;

    申请/专利号US201916404091

  • 发明设计人 KENICHIRO HASUMI;

    申请日2019-05-06

  • 分类号A61K35/15;A61K39/395;C12N5/0784;C12N5/0783;A61K35/17;C07K16/24;A61K38/19;

  • 国家 US

  • 入库时间 2022-08-21 11:20:59

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号